Head-to-head · free

Amgen vs BioStem Technologies, Inc.

AMGN vs BSEM — return on capital, cash generation, margins and balance sheet side by side.

AMGN

0 / 0

measures where AMGN leads

BSEM

0 / 0

measures where BSEM leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureAMGN · FY2025BSEM
Revenue$36.8B—
Net income$7.7B—
Revenue growth (yearly, multi-year)9.1%—
Free cash flow$8.1B—
Free cash flow margin22.0%—
Net cash / (debt)——
ROIC11.8%—
Return on equity106.1%—
Gross margin67.2%—
Operating margin24.7%—
Net debt / EBITDA3.19x—

Figures are as reported by each company; latest fiscal year shown.

Where Amgen's cash went (FY2025)

Capital spending
$1.9B
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full AMGN profile →

Where BioStem Technologies, Inc.'s cash went

Not reported yet.

Full BSEM profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons